IP Library Granted Patent US 9,944,647
Granted Patent B2
US 9,944,647 · App. 15/088,259 · Granted Apr 17, 2018

Heterocyclic compounds as LSD1 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,944,647
App. No.
15/088,259
Granted
Apr 17, 2018
Kind
B2
Abstract

The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claims (12)

1. A compound which is 4-[5-[4-(dimethylamino)piperidin-1-yl]-8-(1-methyl -1H-pyrazolo[3,4-b]pyridin-5-yl)imidazo[1,2-c]pyrimidin-7-yl]benzonitrile, or a pharmaceutically acceptable salt thereof.

2. A compound which is 4-[5-[4-(dimethylamino)piperidin-1-yl]-8-(1-methyl -1H-pyrazolo[3,4-b]pyridin-5-yl)imidazo[1,2-c]pyrimidin-7-yl]benzonitrile.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

4. A pharmaceutical composition comprising the compound of claim 2 and at least one pharmaceutically acceptable carrier or excipient.

5. A compound which is 4-[5-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-8-(1-methyl -1H-pyrazolo[3,4-b]pyridin-5-yl)imidazo[1,2-c]pyrimidin-7-yl]benzonitrile, or a pharmaceutically acceptable salt thereof.

6. A compound which is 4-[5-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-8-(1-methyl -1H-pyrazolo[3,4-b]pyridin-5-yl)imidazo[1,2-c]pyrimidin-7-yl]benzonitrile.

7. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

8. A pharmaceutically composition comprising the compound of claim 6 and at least one pharmaceutically acceptable carrier or excipient.

9. A compound which is 4-[5-[4-(dimethylamino)piperidin-1-yl]-8-(1-methyl -1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-c]pyrimidin-7-yl]benzonitrile, or a pharmaceutically acceptable salt thereof.

10. A compound which is 4-[5-[4-(dimethylamino)piperidin-1-yl]-8-(1-methyl -1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-c]pyrimidin-7-yl]benzonitrile.

11. A pharmaceutical composition comprising the compound of claim 9 , a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

12. A pharmaceutical composition comprising the compound of claim 10 and at least one pharmaceutically acceptable carrier or excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: INCYTE CORPORATION
To: INCYTE CORPORATION; INCYTE HOLDINGS CORPORATION
Reel/Frame 058815/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2016
From: HE, CHUNHONG; LI, ZHENWU; WU, LIANGXING; YAO, WENQING; ZHANG, FENGLEI
To: INCYTE CORPORATION
Reel/Frame 038242/0001 →